Artivion Inc AORT

NYS: AORT | ISIN: US2289031005   30/06/2025
31,10 USD (-0,29%)
(-0,29%)   30/06/2025

14 mei 2025 · Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock · Persbericht

5 mei 2025 · Artivion Reports First Quarter 2025 Financial Results · Persbericht

5 mei 2025 · Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting · Persbericht

21 april 2025 · Artivion Announces Release Date and Teleconference Call Details for First Quarter 2025 Financial Results · Persbericht

4 maart 2025 · Artivion to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference · Persbericht

8 augustus 2024 · Artivion Reports Second Quarter 2024 Financial Results · Persbericht

5 augustus 2024 · Artivion to Participate in Upcoming Investor Conferences · Persbericht

25 juli 2024 · Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results · Persbericht

1 juli 2024 · Artivion Amends Agreements with Endospan · Persbericht

6 mei 2024 · Artivion Reports First Quarter 2024 Financial Results · Persbericht

29 april 2024 · Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting · Persbericht

22 april 2024 · Artivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial Results · Persbericht

1 april 2024 · Artivion to Participate in the 23rd Annual Needham Virtual Healthcare Conference · Persbericht

6 maart 2024 · Artivion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference · Persbericht

15 februari 2024 · Artivion Reports Fourth Quarter and Full Year 2023 Financial Results · Persbericht

1 februari 2024 · Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2023 Financial Results · Persbericht

29 januari 2024 · Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 60th Society of Thoracic Surgery Annual Meeting · Persbericht

18 januari 2024 · Artivion Obtains $350 Million in Senior Secured Credit Facilities · Persbericht

6 december 2023 · Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D. Ashley Lee, Chief Financial Officer · Persbericht

9 november 2023 · Artivion Announces Completion of Enrollment in PERSEVERE Trial · Persbericht

Mijn selecties